Adma Biologics | ADMA - Interest Expense On Debt


Adma Biologics reported $1.68M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Adma Biologics USD 1.68M 150K Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Novavax USD 5.82M 342K Dec/2025
Omeros USD 4.05M 5.16M Sep/2024
Takeda JPY 123.63B 40.49B Dec/2025